PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
London (PRWEB) November 04, 2013 -- PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
Summary
Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.
The UK NSCLC market is expected to decrease by 2022 at a negative CAGR. As in the rest of the 5EU, contraction will be driven in part by patent expirations for the major marketed therapies Alimta, Avastin, Iressa and Tarceva.
Scope
-Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the UK from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the UK NSCLC market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in the UK.
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology and Histology 15
3.1.3 NSCLC Biomarkers 16
3.1.4 Quality of Life 17
3.2 Symptoms 18
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Diagnosis 21
4.1.2 Clinical Staging 22
4.1.3 Screening and Early Detection 24
4.1.4 Localized Procedures and Therapies 25
4.1.5 Systemic Chemotherapy 26
4.1.6 Targeted Therapy 26
4.2 UK 29
4.2.1 Diagnosis 29
4.2.2 Clinical Practice 29
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles – Major Brands, Chemotherapies 34
5.3.1 Alimta (pemetrexed disodium) 34
5.4 Product Profiles – Major Brands, Targeted Therapies 38
5.4.1 Iressa (gefitinib) 38
5.4.2 Tarceva (erlotinib hydrochloride) 43
5.4.3 Xalkori (crizotinib) 49
5.4.4 Avastin (bevacizumab) 53
6 Opportunity and Unmet Need 57
6.1 Overview 57
6.2 Improved Overall Survival and Less Toxicity 58
6.3 Treatments for Patients with Acquired TKI Resistance 59
6.4 Better Treatment Options for Squamous Patients 60
6.5 Preventing Relapse or Recurrence 60
6.6 More Efficacious Second-Line Therapies 61
6.7 Increased Availability of Mutation Testing 61
6.8 More Cost-Effective Therapies 62
6.9 Unmet Needs Gap Analysis 63
7 Pipeline Assessment 67
7.1 Overview 67
7.2 Promising Drugs in Clinical Development 67
7.2.1 onartuzumab (MetMab) 71
7.2.2 necitumumab (IMC-11F8) 77
7.2.3 ramucirumab (IMC-1121B) 82
7.2.4 custirsen (OGX-011) 86
7.2.5 ganetespib (STA-9090) 91
7.2.6 nintedanib (BIBF1120) 97
7.2.7 Gilotrif (afatinib) 101
7.2.8 dacomitinib (PF-00299804) 107
7.2.9 LDK378 111
7.2.10 Yervoy (ipilimumab) 116
7.2.11 nivolumab (BMS936558) 120
7.2.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 126
7.2.13 Halaven (eribulin mesylate) 130
8 Market Outlook 135
8.1 United Kingdom 135
8.1.1 Forecast 135
8.1.2 Key Events 138
8.1.3 Drivers and Barriers 139
9 Appendix 142
9.1 Bibliography 142
9.2 Abbreviations 161
9.3 Methodology 165
9.4 Forecasting Methodology 165
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 165
9.4.2 Percent Drug-treated Patients 166
9.4.3 Drugs Included in Each Therapeutic Class 166
9.4.4 Launch and Patent Expiry Dates 167
9.4.5 General Pricing Assumptions 168
9.4.6 Individual Drug Assumptions 171
9.4.7 Generic Erosion 179
9.4.8 Pricing of Pipeline Agents 180
9.5 Physicians and Specialists Included in This Study 182
9.6 Survey of Prescribing Physicians 184
9.7 About the Authors 185
9.7.1 Authors 185
9.7.2 Epidemiologists 186
9.7.3 Global Head of Healthcare 187
9.8 About GlobalData 188
9.9 Disclaimer 188
1.1 List of Tables
Table 1: Symptoms of Disease NSCLC 19
Table 2: Treatment Guidelines for NSCLC 21
Table 3: Stage Definitions for NSCLC 23
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 28
Table 5: Leading Treatments for NSCLC 34
Table 6: Product Profile – Alimta (pemetrexed disodium) 36
Table 7: Alimta SWOT Analysis, 2013 38
Table 8: Product Profile – Iressa (gefitinib) 40
Table 9: Iressa SWOT Analysis, 2013 43
Table 10: Product Profile – Tarceva (erlotinib hydrochloride) 45
Table 11: Tarceva SWOT Analysis, 2013 48
Table 12: Product Profile – Xalkori (crizotinib) 50
Table 13: Xalkori SWOT Analysis, 2013 53
Table 14: Product Profile – Avastin (bevacizumab) 54
Table 15: Avastin SWOT Analysis, 2013 56
Table 16: Overall Unmet Needs – Current Level of Attainment 58
Table 17: Clinical Unmet Needs – Gap Analysis, 2013 64
Table 18: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 68
Table 19: NSCLC – Phase III Pipeline, 2013 69
Table 20: NSCLC – Advantages and Disadvantages of Therapeutic Classes 70
Table 21: Product Profile – onartuzumab (MetMab) 72
Table 22: onartuzumab SWOT Analysis, 2013 77
Table 23: Product Profile – necitumumab (IMC-11F8) 78
Table 24: necitumumab SWOT Analysis, 2013 82
Table 25: Product Profile – ramucirumab (IMC-1121B) 83
Table 26: ramucirumab SWOT Analysis, 2013 86
Table 27: Product Profile – custirsen (OGX-011) 87
Table 28: custirsen SWOT Analysis, 2013 91
Table 29: Product Profile – ganetespib (STA-9090) 92
Table 30: ganetespib SWOT Analysis, 2013 97
Table 31: Product Profile – nintedanib (BIBF-1120) 98
Table 32: nintedanib SWOT Analysis, 2013 101
Table 33: Product Profile – Gilotrif (afatinib) 102
Table 34: Gilotrif SWOT Analysis, 2013 106
Table 35: Product Profile – dacomitinib (PF-00299804) 107
Table 36: dacomitinib SWOT Analysis, 2013 111
Table 37: Product Profile – LDK378 112
Table 38: LDK378 SWOT Analysis, 2013 116
Table 39: Product Profile – Yervoy (ipilimumab) 117
Table 40: Yervoy SWOT Analysis, 2013 120
Table 41: Product Profile – nivolumab (BMS936558) 121
Table 42: nivolumab SWOT Analysis, 2013 126
Table 43: Product Profile – GSK1572932A (MAGE-A3 immunotherapy) 127
Table 44: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 130
Table 45: Product Profile – Halaven (eribulin mesylate) 131
Table 46: Halaven SWOT Analysis, 2013 134
Table 47: Sales Forecasts ($m) for NSCLC in the UK, 2012-2022 136
Table 48: Key Events Impacting Sales for NSCLC in the UK, 2012-2022 138
Table 49: NSCLC Market in the United Kingdom – Drivers and Barriers, 2012–2022 139
Table 50: Five Year Prevalence 166
Table 51: Key Launch Dates 167
Table 52: Key Patent Expiries 168
Table 53: Physicians Surveyed by Country 184
1.2 List of Figures
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 70
Figure 2: Sales for NSCLC in the United Kingdom by Drug, 2012–2022 137
Read the full report:
PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article